Browsing “Revenue ManagementRevenue Management | EVERSANA”

Building a Service Offering from the Research Lab to the Patient’s Home

A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]

Are We Transforming In The Right Way?

Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we see pockets of transformation. The problem is exactly that – “pockets” of transformation. Your product launch strategy has to […]

Streamline Chargeback and Channel Operations

Robert Blank, Managing Consultant at EVERSANA, moderated a panel with industry experts from Sanofi, Zydus, and UCB at CBI’s 15th Annual Commercial Contract and Chargeback Excellence.  The topic: “Process Improvement in Contract Administration and Management — Streamlining Chargeback Operations, GPO Rosters and Channel Operations.” If you missed this presentation, download Robert’s white paper on the […]

Membership Management Challenges and Best Practices

In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted rate. In turn, the GPO leverages its collective purchasing power with the pharmaceutical manufacturers to secure a lower price […]

Pharmaceutical Contracting from Volume to Value

Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies, regulations, organization structures, and systems have held back the tide, industry analysts agree that the tipping point is being […]

Medicaid Drug Classification: Civil Monetary Penalties

On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective immediately, this law enables the Center for Medicare and Medicaid Services (CMS) to impose civil monetary penalties on any […]

Product Master Data Management

This white paper shares  considerations, common pitfalls and key takeaways for manufacturers participating in Medicaid. Recent market and enforcement trends in healthcare further exemplify the transition from a volume to value-based marketplace, as well as the complexities to contain the increasing costs of drugs in the new paradigm. The costs of branded prescription drugs are rising at […]

Medicare Part D: Closing the Coverage Gap

Signed into law on February 9, 2018, the Bipartisan Budget Act (BBA) of 2018 entails significant adjustments to consumer spending under the Medicare Part D prescription drug program. Beginning in 2019, the period of out-of-pocket expenses in Medicare, known colloquially as the coverage gap or donut hole, will be fully covered for beneficiaries. By requiring […]